Verona Pharma price target raised to $77 from $51 at BTIG

Verona Pharma Price Target Raised To $77 From $51 At BTIG

2 weeks from now

Jan 8, 2025  · BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was “impressive”, …

businessinsider.com

Wells Fargo Sticks To Their Buy Rating For Verona Pharma (VRNA)

2 weeks from now

Jan 8, 2025  · In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $74.00. The …

businessinsider.com

Verona Pharma Stock Target Increased, Keeps Buy On Q4 Sales

2 weeks from now

Jan 8, 2025  · Currently trading at $47.97 with a market capitalization of $4.05 billion, VRNA has demonstrated remarkable momentum with a 191% return over the past six months.

investing.com

Verona Pharma Stock Target Raised To $77 At BTIG

2 weeks from now

Jan 7, 2025  · In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations …

investing.com

Verona Pharma Stock Target Raised To $77 At BTIG - Investing.com …

2 weeks from now

In other recent news, Verona Pharma (NASDAQ: VRNA) has reported positive financial developments, including preliminary fourth-quarter sales that exceeded expectations and a …

investing.com

Verona Pharma Price Target Raised To $74 From $64 At Wells Fargo

2 weeks from now

Jan 8, 2025  · Try Now>>See Insiders’ Hot Stocks on TipRanks >> Read More on VRNA:Verona Pharma price target raised to $77 from $51 at BTIGVerona Pharma sees Q4 net product sales …

nasdaq.com

Verona Pharma (NASDAQ:VRNA) Upgraded By Roth Capital To …

2 weeks from now

3 days ago  · NASDAQ:VRNA opened at $45.20 on Friday. The stock has a 50-day moving average price of $41.33 and a 200 day moving average price of $31.64. The stock has a …

etfdailynews.com

Verona Pharma Initiated With A Buy At Roth MKM - Markets Insider

2 weeks from now

5 days ago  · Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its investment thesis is driven by …

businessinsider.com

Verona Posts Sales Figures For Q4 And 2024 (VRNA:NASDAQ)

2 weeks from now

Jan 7, 2025  · Citing preliminary unaudited results on Tuesday, Verona Pharma (NASDAQ:VRNA) reported ~$36M and $42M in net product sales for Q4 and the full year 2024, respectively, …

seekingalpha.com

Verona Pharma (NASDAQ:VRNA) Stock, Analyst Ratings, Price …

2 weeks from now

Pre-Market: 4:00 PM EDT. Get Report. ... The low is $31 issued by BTIG on ... (VRNA) rating was a maintained with a price target of $50.00 to $64.00. The current price Verona Pharma …

benzinga.com

Verona Pharma's Promising COPD Treatment Puts It In GSK's

2 weeks from now

Dec 29, 2023  · The analysts Raghuram Selvaraju and Boobalan Pachaiyappan reiterate a Buy rating and a price target of $32. Price Action: VRNA shares are down 0.64% at $20.03 on the …

benzinga.com

Verona Pharma Price Target Raised To $74 From $64 At ... - Markets …

2 weeks from now

Jan 8, 2025  · Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the shares. The firm notes …

businessinsider.com

Verona Pharma Price Target Raised To $57 From $44 At Truist

2 weeks from now

Jan 8, 2025  · Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the company’s positive Q4 revenue pre …

businessinsider.com

Truist Financial Remains A Buy On Verona Pharma (VRNA)

2 weeks from now

Jan 6, 2025  · Currently, the analyst consensus on Verona Pharma is a Strong Buy with an average price target of $50.20. See Insiders’ Hot Stocks on TipRanks >> VRNA market cap is …

businessinsider.com